Symbicort 160/4.5mcg (120 Oral Inh)

Manufacturer ASTRA ZENECA Active Ingredient Budesonide and Formoterol Inhalation Aerosol(byoo DES oh nide & for MOH te rol) Pronunciation byoo-DES-oh-nide & for-MOH-te-rol
It is used to treat COPD (chronic obstructive pulmonary disease).It is used to treat asthma.Do not use this drug to treat intense flare- ups of shortness of breath. Use a rescue inhaler. If you have questions, talk with the doctor.
🏷️
Drug Class
Bronchodilator/Corticosteroid Combination
🧬
Pharmacologic Class
Inhaled Corticosteroid (ICS) / Long-Acting Beta2-Adrenergic Agonist (LABA)
🀰
Pregnancy Category
Category C
βœ…
FDA Approved
Aug 2006
βš–οΈ
DEA Schedule
Not Controlled

Overview

ℹ️

What is this medicine?

Symbicort is an inhaler that contains two medicines: a corticosteroid (budesonide) to reduce inflammation in your lungs, and a long-acting bronchodilator (formoterol) to help open your airways. It's used regularly, twice a day, to help prevent asthma attacks or improve breathing in COPD. It is NOT for sudden breathing problems.
πŸ“‹

How to Use This Medicine

Proper Use of This Medication

To use this medication correctly, follow your doctor's instructions and read all the information provided. Use this inhaler only for breathing in, as directed by your healthcare provider. Continue using this medication even if you feel well, unless your doctor tells you to stop.

Preparing and Using the Inhaler

Before using the inhaler for the first time, or if it has not been used for more than 7 days, or if it has been dropped, prepare it by spraying 2 test sprays into the air. Shake the inhaler well for 5 seconds before each test spray. Before each use, shake the inhaler well for 5 seconds. After using the inhaler, rinse your mouth with water, but do not swallow the water. Spit it out. Replace the cap on the inhaler after each use.

Tracking Your Doses

The inhaler has a dose counter that keeps track of how many doses are left. Dispose of the inhaler when you are told to do so after opening, or when the dose counter reaches "0", whichever comes first. Never wash the inhaler, and keep it dry.

Using Multiple Inhaled Medications

If you are using more than one inhaled medication, ask your doctor which medication to use first.

Accidental Exposure

If you get this medication in your eyes, rinse them immediately with water. If you experience eye irritation that lasts or a change in vision, call your doctor.

Storage and Disposal

Store this medication at room temperature. Dispose of any unused medication 3 months after removing it from the foil package. Protect the medication from heat or open flames. Do not puncture or burn the inhaler, even if it seems empty.

Missing a Dose

If you miss a dose, skip it and return to your regular schedule. Do not use two doses at the same time or take extra doses.
πŸ’‘

Lifestyle & Tips

  • Use Symbicort regularly, twice a day, every day, even when you feel well. Do not stop using it without talking to your doctor.
  • Rinse your mouth with water and spit it out after each dose to help prevent a yeast infection (thrush) in your mouth and throat.
  • Do not use Symbicort for sudden breathing problems. Always carry a fast-acting rescue inhaler (like albuterol) for acute symptoms.
  • Learn and practice proper inhaler technique as demonstrated by your healthcare provider.
  • Keep track of your symptoms and how often you use your rescue inhaler. Report any worsening symptoms to your doctor.
  • Avoid triggers that worsen your asthma or COPD (e.g., smoke, allergens, air pollution).
πŸ’Š

Available Forms & Alternatives

Dosing & Administration

πŸ‘¨β€βš•οΈ

Adult Dosing

Standard Dose: Asthma: 2 inhalations of 160/4.5 mcg twice daily. COPD: 2 inhalations of 160/4.5 mcg twice daily.
Dose Range: 2 - 4 mg

Condition-Specific Dosing:

asthma: 2 inhalations of 160/4.5 mcg twice daily (maximum 2 inhalations of 160/4.5 mcg twice daily).
copd: 2 inhalations of 160/4.5 mcg twice daily.
πŸ‘Ά

Pediatric Dosing

Neonatal: Not established
Infant: Not established
Child: Asthma (6-11 years): 2 inhalations of 80/4.5 mcg twice daily. Not approved for 160/4.5 mcg in this age group.
Adolescent: Asthma (>=12 years): 2 inhalations of 80/4.5 mcg or 160/4.5 mcg twice daily.
βš•οΈ

Dose Adjustments

Renal Impairment:

Mild: No specific adjustment recommended.
Moderate: No specific adjustment recommended.
Severe: No specific adjustment recommended.
Dialysis: No specific adjustment recommended; primarily metabolized by liver.

Hepatic Impairment:

Mild: No specific adjustment recommended.
Moderate: Use with caution; budesonide clearance may be reduced.
Severe: Use with caution; budesonide clearance may be significantly reduced, increasing systemic exposure.

Pharmacology

πŸ”¬

Mechanism of Action

Budesonide is an inhaled corticosteroid (ICS) that exerts potent anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting inflammatory cells (e.g., mast cells, eosinophils, lymphocytes, macrophages, neutrophils) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines). This reduces bronchial hyperreactivity and inflammation. Formoterol is a long-acting beta2-adrenergic agonist (LABA) that selectively stimulates beta2-adrenergic receptors in the lung, leading to relaxation of bronchial smooth muscle and bronchodilation. It also inhibits the release of mediators from mast cells.
πŸ“Š

Pharmacokinetics

Absorption:

Bioavailability: Budesonide: Approximately 39% (systemic bioavailability after inhalation). Formoterol: Approximately 43% (systemic bioavailability after inhalation).
Tmax: Budesonide: Approximately 10 minutes (for peak plasma concentration after inhalation). Formoterol: Approximately 10 minutes (for peak plasma concentration after inhalation).
FoodEffect: Not applicable for inhaled administration.

Distribution:

Vd: Budesonide: Approximately 3 L/kg. Formoterol: Approximately 2.3 L/kg.
ProteinBinding: Budesonide: Approximately 85-90%. Formoterol: Approximately 61-64%.
CnssPenetration: Limited

Elimination:

HalfLife: Budesonide: Approximately 2-4 hours. Formoterol: Approximately 10 hours.
Clearance: Budesonide: Approximately 0.9-1.5 L/min. Formoterol: Approximately 0.15 L/min.
ExcretionRoute: Primarily renal (metabolites), minor fecal excretion.
Unchanged: Budesonide: <1% (urine). Formoterol: Approximately 6-10% (urine).
⏱️

Pharmacodynamics

OnsetOfAction: Formoterol: 1-3 minutes (bronchodilation). Budesonide: Anti-inflammatory effects may take 1-2 weeks for full benefit.
PeakEffect: Formoterol: 1-4 hours (bronchodilation). Budesonide: Full therapeutic effect typically seen within 1-2 weeks of regular use.
DurationOfAction: Formoterol: Approximately 12 hours. Budesonide: Sustained anti-inflammatory effect with twice-daily dosing.

Safety & Warnings

⚠️

BLACK BOX WARNING

Long-acting beta2-adrenergic agonists (LABAs), such as formoterol, increase the risk of asthma-related death. Data from a large, randomized, placebo-controlled clinical trial in asthma showed that LABAs increase the risk of asthma-related death. This finding is considered a class effect of LABAs. The safety and effectiveness of Symbicort in patients with asthma have been established in clinical trials. Symbicort is not indicated for the relief of acute bronchospasm.
⚠️

Side Effects

Urgent Side Effects: Seek Medical Help Right Away

Although rare, some people may experience severe and potentially life-threatening side effects while taking this medication. If you notice any of the following symptoms, contact your doctor or seek immediate medical attention:

Signs of an allergic reaction: rash, hives, itching, red, swollen, blistered, or peeling skin (with or without fever), wheezing, tightness in the chest or throat, difficulty breathing, swallowing, or talking, unusual hoarseness, or swelling of the mouth, face, lips, tongue, or throat.
Signs of infection: fever, chills, severe sore throat, ear or sinus pain, cough, increased or changed sputum production, painful urination, mouth sores, or a wound that won't heal.
Signs of high blood sugar: confusion, drowsiness, excessive thirst or hunger, frequent urination, flushing, rapid breathing, or fruity-smelling breath.
Signs of low potassium levels: muscle pain or weakness, muscle cramps, or an irregular heartbeat.
Signs of a weak adrenal gland: severe nausea or vomiting, extreme dizziness or fainting, muscle weakness, fatigue, mood changes, decreased appetite, or weight loss.
Signs of high or low blood pressure: severe headache or dizziness, fainting, or changes in vision.
Chest pain or pressure.
Rapid or abnormal heartbeat.
Shakiness.
Feeling nervous or excitable.
Bone pain.
Dizziness or fainting.
Seizures.
Severe nausea or vomiting.
Extreme fatigue or weakness.
Difficulty sleeping.
Abnormal burning, numbness, or tingling sensations.
Flu-like symptoms.
Sinus pain.
Changes in vision, eye pain, or severe eye irritation.
Redness or white patches in the mouth or throat.
Mouth irritation or mouth sores.

Important Warning: This medication can cause severe breathing problems, which may be life-threatening. If you experience difficulty breathing, worsening breathing, wheezing, or coughing after taking this medication, use a rescue inhaler and seek immediate medical attention.

Other Possible Side Effects

Like all medications, this drug can cause side effects. Many people may not experience any side effects or only minor ones. If you notice any of the following side effects or any other symptoms that bother you or don't go away, contact your doctor:

Headache.
Stomach pain.
Nose or throat irritation.
Signs of a common cold.
Back pain.
Nausea or vomiting.

This is not an exhaustive list of possible side effects. If you have questions or concerns about side effects, contact your doctor. You can also report side effects to the FDA at 1-800-332-1088 or online at https://www.fda.gov/medwatch.
🚨

Seek Immediate Medical Attention If You Experience:

  • Worsening asthma or COPD symptoms (e.g., increased shortness of breath, wheezing, cough, chest tightness)
  • Increased need for your rescue inhaler
  • Chest pain or discomfort
  • Fast or irregular heartbeat (palpitations)
  • Severe tremor or nervousness
  • Signs of infection (e.g., fever, chills, increased mucus, change in mucus color)
  • Signs of an allergic reaction (e.g., rash, hives, swelling of your face, lips, tongue, or throat, severe wheezing or difficulty breathing)
  • Signs of adrenal insufficiency (e.g., severe tiredness, weakness, nausea, vomiting, dizziness, fainting, low blood pressure)
  • New or worsening eye problems (e.g., blurred vision, eye pain, halos around lights)
πŸ“‹

Before Using This Medicine

Before Taking This Medication: Important Information to Share with Your Doctor

It is essential to inform your doctor about the following:

Any allergies you have, including allergies to this medication, its components, or other substances, such as foods or drugs. Be sure to describe the symptoms you experienced.
If you are currently taking another medication similar to this one. If you are unsure, consult your doctor or pharmacist for clarification.

Please note that this is not an exhaustive list of all potential interactions with this medication. To ensure your safety, it is crucial to:

Inform your doctor and pharmacist about all the medications you are taking, including prescription and over-the-counter drugs, natural products, and vitamins.
Discuss all your health problems with your doctor and pharmacist.
Verify that it is safe to take this medication with all your other medications and health conditions.
Never start, stop, or change the dose of any medication without first consulting your doctor.
⚠️

Precautions & Cautions

Important Warnings and Cautions

When taking this medication, it is essential to inform all your healthcare providers, including doctors, nurses, pharmacists, and dentists, about your treatment.

If you have diabetes (high blood sugar), consult your doctor, as this medication may increase your blood sugar levels.

It may take up to 2 weeks to experience the full effects of this medication. If your breathing problems worsen, your rescue inhaler is less effective, or you need to use it more frequently, contact your doctor immediately.

Do not exceed the recommended dose or frequency of this medication, as overdoses have been fatal. Consult your doctor if you have any concerns.

When transitioning from an oral steroid to another form of steroid, you may be at risk for severe and potentially life-threatening side effects, including weakness, fatigue, dizziness, nausea, vomiting, confusion, or low blood sugar. If you experience any of these symptoms, contact your doctor right away.

In cases of injury, surgery, or infection, you may require additional doses of oral steroids to help your body cope with stress. Carry a warning card indicating that you may need extra steroids in such situations.

Long-term use of this medication may increase the risk of cataracts or glaucoma. Consult your doctor and undergo regular eye exams as recommended.

Prolonged use may also lead to osteoporosis (weak bones). Discuss your risk factors and concerns with your doctor.

You may be more susceptible to infections; therefore, practice good hygiene by washing your hands frequently and avoiding people with infections, colds, or flu.

If you have not had chickenpox or measles before, avoid exposure to these illnesses, as they can be severe or even fatal in people taking steroid medications like this one. If you have been exposed, consult your doctor.

If you are 65 or older, use this medication with caution, as you may be more prone to side effects.

In children and teenagers, this medication may affect growth in some cases. Regular growth checks may be necessary; consult your doctor.

If you are pregnant, plan to become pregnant, or are breastfeeding, discuss the benefits and risks of this medication with your doctor.

Specific Warning for COPD Patients

If you have Chronic Obstructive Pulmonary Disease (COPD), you are at a higher risk of developing pneumonia. This medication may further increase this risk; consult your doctor to discuss the potential risks and benefits.
πŸ†˜

Overdose Information

Overdose Symptoms:

  • For formoterol overdose: Tachycardia, palpitations, tremor, headache, nausea, dizziness, hypokalemia, hyperglycemia, metabolic acidosis.
  • For budesonide overdose: Acute overdose is unlikely due to low systemic absorption. Chronic overdose may lead to signs of hypercorticism (e.g., Cushingoid features, adrenal suppression).

What to Do:

Seek immediate medical attention. Call 911 or your local emergency number. For suspected poisoning, contact a poison control center at 1-800-222-1222. Treatment is supportive and symptomatic. Monitor cardiac function (ECG), serum potassium, and blood glucose. Consider judicious use of a cardioselective beta-blocker for severe cardiac symptoms, but only with extreme caution due to risk of bronchospasm.

Drug Interactions

🚫

Contraindicated Interactions

  • Other long-acting beta2-adrenergic agonists (LABAs) - increased risk of cardiovascular adverse effects.
πŸ”΄

Major Interactions

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) - significantly increase systemic exposure to budesonide, leading to potential for Cushing's syndrome and adrenal suppression.
  • Beta-adrenergic blockers (including ophthalmic) - may antagonize the bronchodilating effect of formoterol and produce severe bronchospasm, especially in patients with asthma.
  • QT-prolonging drugs (e.g., quinidine, disopyramide, procainamide, phenothiazines, tricyclic antidepressants) - additive effect on QT interval, increasing risk of ventricular arrhythmias.
  • Diuretics (e.g., loop or thiazide diuretics) - may potentiate hypokalemia and/or ECG changes associated with beta-agonists, especially at high doses.
🟑

Moderate Interactions

  • Tricyclic antidepressants (TCAs) and Monoamine Oxidase Inhibitors (MAOIs) - may potentiate the cardiovascular effects of formoterol (e.g., hypertension, tachycardia). Use with extreme caution.
  • Other sympathomimetic agents - additive effects on cardiovascular system; use with caution.
  • Non-potassium-sparing diuretics - increased risk of hypokalemia.
🟒

Minor Interactions

  • Not specifically categorized as minor; most interactions are significant due to the nature of the active ingredients.

Monitoring

πŸ”¬

Baseline Monitoring

Pulmonary Function Tests (FEV1)

Rationale: To establish baseline lung function and assess disease severity.

Timing: Prior to initiation of therapy.

ECG

Rationale: To assess for baseline cardiac abnormalities, especially in patients with pre-existing cardiovascular disease, due to potential for formoterol to cause QT prolongation or other cardiac effects.

Timing: Prior to initiation, especially if risk factors for cardiac arrhythmias are present.

Serum Potassium and Glucose

Rationale: Formoterol can cause transient hypokalemia and hyperglycemia.

Timing: Prior to initiation, especially in patients with diabetes or conditions predisposing to hypokalemia.

Bone Mineral Density (BMD)

Rationale: Long-term use of inhaled corticosteroids can affect bone density.

Timing: Baseline for patients at risk for osteoporosis.

Ophthalmic Exam (for cataracts/glaucoma)

Rationale: Long-term use of inhaled corticosteroids can increase risk of cataracts and glaucoma.

Timing: Baseline for patients at risk or with pre-existing conditions.

πŸ“Š

Routine Monitoring

Pulmonary Function Tests (FEV1)

Frequency: Periodically (e.g., every 6-12 months or as clinically indicated)

Target: Improvement from baseline, maintenance of optimal lung function.

Action Threshold: Significant decline in FEV1 or lack of improvement may indicate inadequate control or worsening disease.

Asthma/COPD Symptom Control

Frequency: At each clinical visit

Target: Reduced frequency of symptoms, reduced rescue inhaler use, improved quality of life.

Action Threshold: Increased symptoms, increased rescue inhaler use, nocturnal awakenings, or exacerbations indicate need for therapy adjustment.

Growth in Pediatric Patients

Frequency: Regularly (e.g., every 3-6 months)

Target: Normal growth velocity for age.

Action Threshold: Growth retardation may indicate systemic corticosteroid effects; consider dose reduction or alternative therapy.

Serum Potassium and Glucose

Frequency: As clinically indicated, especially in patients with diabetes or risk factors for hypokalemia.

Target: Within normal limits.

Action Threshold: Significant deviations may require intervention or dose adjustment.

Signs of Adrenal Suppression (e.g., fatigue, weight loss, hypotension)

Frequency: Periodically, especially during stress or dose changes.

Target: Absence of symptoms.

Action Threshold: Presence of symptoms requires immediate medical evaluation.

Ophthalmic Exam

Frequency: Annually for patients on long-term therapy.

Target: Absence of cataracts or glaucoma progression.

Action Threshold: Development or progression of cataracts/glaucoma may require ophthalmology referral and therapy re-evaluation.

πŸ‘οΈ

Symptom Monitoring

  • Worsening asthma or COPD symptoms (e.g., increased shortness of breath, wheezing, cough)
  • Increased need for rescue inhaler (short-acting beta-agonist)
  • Chest pain or discomfort
  • Palpitations or rapid heart rate
  • Tremor or nervousness
  • Signs of oral candidiasis (white patches in mouth or throat)
  • Hoarseness or dysphonia
  • Signs of infection (e.g., fever, increased sputum, change in sputum color)
  • Allergic reactions (e.g., rash, hives, swelling of face/mouth/tongue, severe bronchospasm)

Special Patient Groups

🀰

Pregnancy

Symbicort is classified as Pregnancy Category C. There are no adequate and well-controlled studies of Symbicort in pregnant women. Budesonide is generally considered one of the preferred inhaled corticosteroids for asthma management during pregnancy due to extensive human data suggesting low risk. Formoterol has shown reproductive toxicity in animal studies. Symbicort should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Trimester-Specific Risks:

First Trimester: Potential for increased risk of congenital malformations with formoterol, though human data for LABAs are limited. Budesonide has not shown increased risk.
Second Trimester: Risk of fetal growth restriction or other adverse outcomes with uncontrolled asthma. Benefits of controlled asthma generally outweigh risks of medication.
Third Trimester: Potential for transient neonatal hypoglycemia or hypokalemia due to beta-agonist effects if used close to delivery. Risk of adrenal suppression in neonate with high-dose ICS, though rare with inhaled forms.
🀱

Lactation

Budesonide is excreted into human milk, but at therapeutic doses, the amount is considered negligible and unlikely to harm a breastfed infant. Formoterol is also excreted into human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Symbicort and any potential adverse effects on the breastfed infant from Symbicort or from the underlying maternal condition. Use with caution.

Infant Risk: Low risk for budesonide; potential for low systemic exposure to formoterol in infant, but adverse effects are unlikely at therapeutic maternal doses.
πŸ‘Ά

Pediatric Use

Approved for asthma in patients 6 years of age and older. Not approved for COPD in pediatric patients. Monitor growth velocity in pediatric patients receiving inhaled corticosteroids, as they may cause a reduction in growth velocity. The lowest effective dose should be used.

πŸ‘΄

Geriatric Use

No specific dosage adjustment is required based on age. However, elderly patients may be more susceptible to the cardiovascular effects of beta-agonists (e.g., tremor, palpitations, increased heart rate, blood pressure changes) and may have comorbidities (e.g., cardiovascular disease, diabetes, osteoporosis, glaucoma) that require careful monitoring or dose adjustment of concomitant medications. Use with caution and monitor for adverse effects.

Clinical Information

πŸ’Ž

Clinical Pearls

  • Symbicort is a maintenance medication and should be used consistently, twice daily, not as a rescue inhaler for acute symptoms.
  • Proper inhaler technique is crucial for effective drug delivery. Patients should be instructed and re-instructed on how to use the inhaler correctly.
  • Rinsing the mouth with water and spitting it out after each dose helps prevent oral candidiasis (thrush) and dysphonia.
  • Patients should always have a short-acting beta-agonist (SABA) rescue inhaler available for acute bronchospasm.
  • The Black Box Warning for LABAs applies to the formoterol component, emphasizing that LABAs should not be used as monotherapy for asthma and that Symbicort is not for acute relief.
  • Monitor for systemic corticosteroid effects, especially with high doses or prolonged use, such as adrenal suppression, bone density changes, and ocular effects (cataracts, glaucoma).
πŸ”„

Alternative Therapies

  • Inhaled Corticosteroid (ICS) monotherapy (e.g., budesonide, fluticasone, mometasone)
  • Long-Acting Beta2-Adrenergic Agonist (LABA) monotherapy (not for asthma, e.g., formoterol, salmeterol)
  • Long-Acting Muscarinic Antagonist (LAMA) (e.g., tiotropium, umeclidinium)
  • Short-Acting Beta2-Adrenergic Agonist (SABA) (e.g., albuterol, levalbuterol)
  • Oral corticosteroids (for exacerbations or severe disease)
  • Leukotriene receptor antagonists (e.g., montelukast)
  • Phosphodiesterase-4 inhibitors (e.g., roflumilast - for severe COPD)
  • Biologic therapies (e.g., omalizumab, mepolizumab, benralizumab, dupilumab - for severe asthma)
πŸ’°

Cost & Coverage

Average Cost: Varies widely, typically $300-$500+ per 120 actuations inhaler
Generic Available: Yes
Insurance Coverage: Tier 2 or Tier 3 (Preferred Brand or Non-Preferred Brand) on most commercial and Medicare Part D plans.
πŸ“š

General Drug Facts

If your symptoms or health issues persist or worsen, it's essential to contact your doctor for further guidance. To ensure your safety, never share your medication with others or take someone else's medication. Some medications may come with an additional patient information leaflet, so be sure to check with your pharmacist for more information. If you have any questions or concerns about this medication, don't hesitate to reach out to your doctor, nurse, pharmacist, or other healthcare provider. In the event of a suspected overdose, immediately call your local poison control center or seek emergency medical attention. When seeking help, be prepared to provide details about the medication, including the amount taken and the time it happened, to ensure you receive the best possible care.